Murphy Analytics Initiates Research Coverage on Tibet Pharmaceuticals (TBET)

Tibet Pharmaceuticals, Inc. TBET, an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth nitiation report by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics. In his report, Mr. Murphy discusses Tibet Pharmaceuticals, its current portfolio of five traditional Tibetan medicine products, and initiates coverage with a 12-month price target of $11.00 per share.